Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

14drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: OBI ×

OBI

This drug is selected. Its supporting articles are shown below.

OBI3

Articles mentioning OBI

3 articles · page 1 of 1

PT2:06 Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: exploratory analyses of the phase III regency trial

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

84.3%

obinutuzumab OBI PBO ST lupus nephritis NCT04221477

…es The REGENCY trial ( NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achie…

Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial

bmjopen · abstract · 2025-12-24 · 3 matching annotations

89.5%

rituximab Obinutuzumab OBI RTX Sud Méditerrannée 2 Agence Nationale de Sécurité du Médicament et des Produits de Santé Comité de Protection des Personnes

…20 monoclonal antibody that has demonstrated its superiority to rituximab (RTX) in vitro and in vivo. Our assumption is that a single inf…

PO:11:279 Serious infection events associated with obinutuzumab in lupus nephritis: a secondary analysis of the phase III regency trial

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

77.8%

obinutuzumab OBI COVID-19 lupus nephritis NCT04221477 LN

…renal response at Week 76, with a manageable safety profile for obinutuzumab. This study aimed to further characterise the occurrence of ser…